News

Night Read (Minnesota): Burrill bets $8 million on St. Paul biopharm start-up

In a speech at the annual meeting of the Rochester Economic Development Corp., Burrill was still short on details on the Elk Run BioBusiness Park in Pine Island.

Here are some news/notes from a day in MedCity, Minnesota:

San Francisco financier Steve Burrill announced Friday that his firm will invest $8 million in Nora Therapeutics, a St. Paul-based biopharmaceuticals company, according to Finance & Commerce in Minneapolis. This raises the number of Minnesota firms to receive investment from Burrill to two, and he signaled that more investments may be on the way. In December, Burrill invested in Segetis, a Golden Valley-based green chemistry company, which is trying to produce everyday plastic goods that require petroleum from plant-based materials.

presented by

Minnesota will get more than $30 million out of nearly $1 billion in federal economic stimulus cash meant to educate health care workers on information technology in their field, according to the Minneapolis-St. Paul Business Journal. Stratis Health, a non-profit organization in Bloomington, will get more than half of those funds.

St. Jude Medical Inc., a medical device maker based in Little Canada,  is expanding in the Austin, Texas area, signing a lease for 85,000 square feet as it positions itself for growth, according to the Austin American Statesman. The new facilities will allow the company to expand its training capabilities as it continues to innovate and train people on new technologies and devices, said Mike Rousseau, group president in Austin for St. Jude.

St. Jude Medical announced European CE Mark approval and first implants of its Fortify and Fortify ST implantable cardioverter defibrillators (ICD) and Unify defibrillators, according to TradingMarkets.com. The company said the smaller devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year.